HC Wainwright Lowers CorMedix (NASDAQ:CRMD) Price Target to $13.00

CorMedix (NASDAQ:CRMD) had its price objective dropped by analysts at HC Wainwright from $18.00 to $13.00 in a research note issued to investors on Friday, Marketbeat Ratings reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 78.82% from the company’s current price. HC Wainwright also issued estimates for CorMedix’s Q1 2026 earnings at $0.73 EPS and FY2030 earnings at $2.47 EPS.

Other analysts have also issued reports about the company. D. Boral Capital reiterated a “buy” rating and set a $14.00 price objective on shares of CorMedix in a report on Thursday, January 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of CorMedix in a research report on Wednesday. D Boral Capital upgraded CorMedix from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Royal Bank Of Canada set a $13.00 price target on CorMedix and gave the company an “outperform” rating in a research note on Wednesday. Finally, Truist Financial set a $16.00 price objective on CorMedix in a report on Thursday, January 8th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $15.86.

CorMedix Trading Down 2.3%

NASDAQ:CRMD opened at $7.27 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.94 and a quick ratio of 1.73. CorMedix has a fifty-two week low of $5.60 and a fifty-two week high of $17.43. The stock’s 50-day moving average is $10.14 and its two-hundred day moving average is $11.22. The stock has a market cap of $572.80 million, a PE ratio of 3.53 and a beta of 1.36.

CorMedix (NASDAQ:CRMD) last posted its quarterly earnings results on Wednesday, November 12th. The company reported $1.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.78. CorMedix had a net margin of 75.83% and a return on equity of 51.77%. The business had revenue of $104.28 million during the quarter, compared to analyst estimates of $65.63 million. During the same period in the prior year, the firm earned ($0.05) earnings per share. The firm’s revenue was up 810.2% compared to the same quarter last year. As a group, equities research analysts forecast that CorMedix will post -0.32 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Joseph Todisco sold 30,000 shares of CorMedix stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $12.00, for a total value of $360,000.00. Following the transaction, the chief executive officer owned 509,496 shares in the company, valued at $6,113,952. This trade represents a 5.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Steven W. Lefkowitz sold 40,000 shares of the business’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $11.88, for a total transaction of $475,200.00. Following the transaction, the director directly owned 80,498 shares of the company’s stock, valued at approximately $956,316.24. This represents a 33.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 90,000 shares of company stock valued at $1,095,200 over the last 90 days. 3.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CorMedix

Institutional investors have recently made changes to their positions in the business. Comerica Bank boosted its stake in CorMedix by 454.6% during the 3rd quarter. Comerica Bank now owns 2,690 shares of the company’s stock valued at $31,000 after purchasing an additional 2,205 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of CorMedix during the second quarter worth approximately $42,000. Caitong International Asset Management Co. Ltd boosted its position in shares of CorMedix by 666.6% in the third quarter. Caitong International Asset Management Co. Ltd now owns 4,385 shares of the company’s stock valued at $51,000 after acquiring an additional 3,813 shares during the period. USA Financial Formulas acquired a new stake in shares of CorMedix in the second quarter worth $55,000. Finally, State of Alaska Department of Revenue acquired a new stake in shares of CorMedix in the third quarter worth $54,000. 34.18% of the stock is currently owned by institutional investors.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.